Smooth muscle chemical pacemaker

• US 5,383,873 A
• Filed: 12/09/1992
• Issued: 01/24/1995
• Est. Priority Date: 12/09/1992
• Status: Expired due to Fees

• Current Assignee: Regents of The University of Minnesota (University of Minnesota)
• Original Assignee: Regents of The University of Minnesota (University of Minnesota)
• Inventors: Hoey, Michael, Gehlbach, Peter
• Primary Examiner(s): Rosenbaum, C. Fred
• Assistant Examiner(s): SMITH, CHALIN A
• Application Number:
  US07/987,748
• Time in Patent Office: 776 Days
• Field of Search: 604/890.1-892.1, 604/19, 128/898, 424/422-426, 424/473, 424/486-490
• US Class Current: 604/891.1
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/2036 Silicones; Polysiloxanes
• CPC Class Codes: Y10S 206/828 Medicinal content

Abstract

Methods and articles of manufacture are provided for treating disorders of smooth muscle function in organ systems. A treatment element comprises a biocompatible polymer matrix loaded with a neuroactive substance. The device is placed in contact with the targeted organ system in a manner effecting a therapeutic effect on the smooth muscle function of the organ system.

Claims

1. A method for treating a disorder associated with smooth muscle function in an organ peripheral to the central nervous system, comprising:

(a) selecting at least one neuroactive substance having a therapeutic effect on said disorder;

(b) selecting means for controlled, localized delivery of said substance to said organ;

(c) combining said at least one neuoractive substance with said means for controlled, localized delivery to form a treatment element; and

(d) attaching said treatment element to a selected portion of the serosa of said organ in a manner to accomplish said therapeutic effect.

2. The method of claim 1, wherein said organ is a mammalian gastrointestinal tract.

3. The method of claim 1, wherein said organ is a mammalian intestinal tract.

4. The method of claim 3, wherein said mammalian intestinal tract is a human intestinal tract.

5. The method of claim 1, wherein said organ is a urinary bladder.

6. The method of claim 1, wherein said organ is a uterus.

7. The method of claim 1, wherein said organ is a body sphincter.

8. The method of claim 2, wherein said disorder is an adynamic condition of said gastrointestinal tract.

9. The method of claim 2, wherein said disorder is a hypodynamic condition of said gastrointestinal tract.

10. The method of claim 2, wherein said disorder is a hyperdynamic condition of said gastrointestinal tract.

11. The method of claim 2, wherein said neuroactive substance is barium chloride.

12. The method of claim 2, wherein said neuroactive substance is a neurotransmitter.

13. The method of claim 12, wherein said neurotransmitter is selected from the group consisting of acetylcholine, methacholine, and pilocarpine.

14. The method of claim 13, wherein said neurotransmitter is acetylcholine.

15. The method of claim 1 wherein said means for controlled, localized delivery comprises a biocompatible polymer matrix adapted for contact with said organ.

16. The method of claim 15 wherein said treatment element comprises said neuroactive substance in combination with said polymer matrix, said neuroactive substance being dispersed within said matrix, said matrix having a shape and a size adapted for therapeutically useful contact with said organ.

17. The method of claim 16 wherein said contact is with a mammalian gastrointestinal tract.